Diabetic Ketoacidosis Treatment MarketSize and Trends

Global Diabetic Ketoacidosis Treatment Market: Drivers

The rising prevalence of diabetes and diabetic ketoacidosis is a major global concern. According to the U.S National Library of Health, the frequency of diabetic ketoacidosis in adults with type1 diabetes is high, and approximately one third of the adults has severe conditions such as diabetes type-1 and diabetic ketoacidosis. Moreover, healthcare providers are focused on spreading awareness regarding diabetes type 1 and diabetic ketoacidosis. For instance, in April 2020, Diabetes UK, a healthcare and research charity association in England, stated that the National Health Services should be kept open for emergency conditions such diabetic ketoacidosis as they may lead to life threating situation.

Global Diabetic Ketoacidosis Treatment Market: Impact of COVID-19

There is a two-directional relationship between diabetes and COVID-19. According to the Lancet, diabetes is associated with high risk of COVID-19 infection and secondly people with diabetes who have infected with COVID-19 need higher dose of insulin to avoid severe condition such as diabetic ketoacidosis. Moreover, healthcare professionals are facing several challenges in terms of managing patients in intensive care unit undergoing treatment of diabetic ketoacidosis. This is owing to the increasing burden on ICUs for treating critical cases of COVID-19. These factors are expected to hamper the growth of global diabetic ketoacidosis treatment market.

Market Trends

Common chronic conditions like diabetes and its associated complications, such as diabetic ketoacidosis, pose major burdens in regions like North America. According to the Centers for Disease Control and Prevention, till 2015, around 30 million people in the U.S. had diabetes and recorded significant increase in annual average rate of 6.3% from 2009 to 2014 of persons hospitalized due to diabetic ketoacidosis. Moreover, pharmaceutical companies are focusing on direct treatment or increasing availability of supportive treatments for diabetic ketoacidosis to meet market needs. For example, in June 2020, Lexicon Pharmaceutical Inc. announced the use of Zynquista (sotagliflozin) to balance the risk of diabetic ketoacidosis in adults with type-1 diabetes.